Product NDC: | 50242-080 |
Proprietary Name: | LUCENTIS |
Non Proprietary Name: | RANIBIZUMAB |
Active Ingredient(s): | 10 mg/mL & nbsp; RANIBIZUMAB |
Administration Route(s): | INTRAVITREAL |
Dosage Form(s): | INJECTION, SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 50242-080 |
Labeler Name: | Genentech, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | BLA125156 |
Marketing Category: | BLA |
Start Marketing Date: | 20060630 |
Package NDC: | 50242-080-01 |
Package Description: | 1 VIAL, SINGLE-USE in 1 CARTON (50242-080-01) > .05 mL in 1 VIAL, SINGLE-USE |
NDC Code | 50242-080-01 |
Proprietary Name | LUCENTIS |
Package Description | 1 VIAL, SINGLE-USE in 1 CARTON (50242-080-01) > .05 mL in 1 VIAL, SINGLE-USE |
Product NDC | 50242-080 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | RANIBIZUMAB |
Dosage Form Name | INJECTION, SOLUTION |
Route Name | INTRAVITREAL |
Start Marketing Date | 20060630 |
Marketing Category Name | BLA |
Labeler Name | Genentech, Inc. |
Substance Name | RANIBIZUMAB |
Strength Number | 10 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Vascular Endothelial Growth Factor Receptor Inhibitors [MoA],Vascular Endothelial Growth Factor-directed Antibody [EPC],Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA] |